IFS Group’s Pfizer PFE Stock Holding History

IFS Group’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,694	Closed	-$356K	–	119
2026 Q1	$356K	Buy	+12,694	New	+$338K	0.32%	90
2025 Q3	$388K	Buy	+14,250	New	+$352K	0.34%	81

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

IFS Group's PFE Position: Q2 2026 in Review

IFS Group sold out of Pfizer (PFE) in Q2 2026, closing a stake of 12,694 shares — an estimated $356K sold.

IFS Group first reported a position in PFE in Q3 2025 and held it in 2 quarters. The position peaked at $388K in Q3 2025. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

IFS Group reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
IFS Group sold 12,694 Pfizer shares in Q2 2026, an estimated $356K.
IFS Group first reported a position in Pfizer in Q3 2025 and held it in 2 quarters.
IFS Group's Pfizer position peaked at $388K in Q3 2025.
2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on IFS Group's 13F filing for Q2 2026, filed 23 Jul 2026.